Adverse reactions related to hypotension (hypotension, orthostatic hypotension, and decreased blood pressure) were reported in 1.3% of semaglutide-treated patients versus 0.4% of placebo-treated patients during clinical trials of the semaglutide injection for weight management
[DOI] [PubMed] [Google Scholar] 57.Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A.G., Rogliani P., Matera M.G
And I think there's a lot of industry influence and spit being swapped that can skew decisions and viewpoints, and that's dangerous
doi: 10.1259/bjr.20180037 217 DuGLiuTLewisMMKongLWangYConnorJet al
Individual peptide research material
The practical takeaway is that even a temporary course of retatrutide provides metabolic value beyond the weight loss itself